7,115 Johnson & Johnson $JNJ Shares Purchased by Sumitomo Mitsui DS Asset Management Company Ltd

Posted by Stanley Muller on Oct 22nd, 2026

Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 1.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 607,323 shares of the company’s stock after acquiring an additional 7,115 shares during the quarter. Johnson & Johnson comprises approximately 1.1% of Sumitomo Mitsui DS Asset Management Company Ltd’s portfolio, making the stock its 17th largest holding. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Johnson & Johnson were worth $160,783,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Wellington Management Group LLP grew its holdings in shares of Johnson & Johnson by 12.5% during the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after purchasing an additional 2,513,321 shares during the last quarter. Deutsche Bank AG increased its position in shares of Johnson & Johnson by 8.5% during the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock worth $3,977,506,000 after purchasing an additional 1,225,676 shares in the last quarter. Amundi increased its position in shares of Johnson & Johnson by 17.5% during the first quarter. Amundi now owns 13,406,820 shares of the company’s stock worth $3,277,163,000 after purchasing an additional 2,001,139 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Johnson & Johnson by 1.9% in the 1st quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company’s stock valued at $1,924,323,000 after purchasing an additional 148,497 shares during the last quarter. Finally, Jupiter Topco LLC purchased a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $1,967,399,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Wells Fargo & Company upped their target price on Johnson & Johnson from $275.00 to $287.00 and gave the company an “overweight” rating in a research report on Friday, October 16th. Leerink Partners cut their price target on Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 14th. Scotiabank reaffirmed an “outperform” rating and set a $305.00 price target on shares of Johnson & Johnson in a research report on Thursday, July 16th. JPMorgan Chase & Co. boosted their price objective on Johnson & Johnson from $270.00 to $285.00 and gave the company a “neutral” rating in a research note on Tuesday, September 29th. Finally, Johnson Rice downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $275.92.

View Our Latest Stock Analysis on JNJ

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: Johnson & Johnson raised its 2026 outlook, calling for approximately $101.2 billion in sales at the midpoint and adjusted earnings per share of $11.05–$11.15. Its latest quarter also modestly exceeded expectations, with adjusted EPS of $2.59 versus the $2.53 consensus and revenue of $25.40 billion. Johnson & Johnson Drugs Lift Guidance, but Is 23 Times Earnings Fair?
Positive Sentiment: The company extended its dividend-growth streak to 64 consecutive years, supporting its appeal to income-focused investors despite weaker reported earnings. Johnson & Johnson’s Profit Fell 96% Year-Over-Year
Positive Sentiment: MedTech momentum includes the U.S. launch of the Shockwave C2 Aero Fly coronary IVL catheter, designed to reduce treatment time and strengthen J&J’s cardiovascular-device franchise. TD Cowen reiterated a Buy rating with a $300 price target. Johnson & Johnson Launches Next-Generation Shockwave Catheter

Insider Activity

In related news, EVP Jennifer L. Taubert sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the sale, the executive vice president owned 194,451 shares in the company, valued at $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the completion of the sale, the executive vice president directly owned 16,994 shares in the company, valued at $4,367,458. This represents a 48.37% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 64,515 shares of company stock valued at $17,271,766 over the last quarter. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $257.64 on Thursday. The stock has a fifty day moving average price of $265.46 and a 200 day moving average price of $249.94. Johnson & Johnson has a 1-year low of $184.66 and a 1-year high of $281.07. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The company has a market cap of $620.90 billion, a PE ratio of 39.04, a P/E/G ratio of 2.56 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. The company had revenue of $25.40 billion for the quarter, compared to analysts’ expectations of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.54%. Johnson & Johnson’s revenue was up 5.9% compared to the same quarter last year. During the same period in the previous year, the company posted $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Sell-side analysts forecast that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. Johnson & Johnson’s payout ratio is presently 81.21%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.